Overview

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

Status:
COMPLETED

Trial end date:
2024-06-21

Target enrollment:

Participant gender:

Summary

The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Alendronate
MK-0616